Danaher Co. (NYSE:DHR) Shares Acquired by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. increased its position in shares of Danaher Co. (NYSE:DHR) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,422 shares of the conglomerate’s stock after purchasing an additional 561 shares during the period. First Citizens Bank & Trust Co.’s holdings in Danaher were worth $9,279,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DHR. Coronation Fund Managers Ltd. boosted its holdings in Danaher by 29.9% in the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after purchasing an additional 1,470 shares in the last quarter. Peloton Wealth Strategists boosted its holdings in shares of Danaher by 1.3% in the 2nd quarter. Peloton Wealth Strategists now owns 5,764 shares of the conglomerate’s stock valued at $1,440,000 after buying an additional 75 shares in the last quarter. Oliver Lagore Vanvalin Investment Group grew its position in shares of Danaher by 12.3% in the 2nd quarter. Oliver Lagore Vanvalin Investment Group now owns 4,098 shares of the conglomerate’s stock valued at $1,024,000 after buying an additional 448 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Danaher during the 2nd quarter worth $209,000. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Danaher by 2.0% in the 2nd quarter. Texas Capital Bank Wealth Management Services Inc now owns 32,138 shares of the conglomerate’s stock valued at $8,030,000 after purchasing an additional 628 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.1 %

Shares of DHR opened at $245.95 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The stock has a market cap of $177.65 billion, a PE ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The stock’s 50-day moving average is $235.33 and its two-hundred day moving average is $253.45.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a report on Thursday, October 31st. Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Evercore ISI upped their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.